In this edition of Weekly Extractions, host Adam Tubero breaks down his thoughts on the results of atai Life Science‘s ($ATAI) Deuterated Mitragynine (KUR-101) and R-Ketamine (PCN-101) recent trial results.
Watch the video below for all of the details.
The results aren’t ideal, and atai’s stock price has obviously been impacted. That said, it’s always important to understand the finer details and what this means for the company over the long term.
Please like, share, comment, and subscribe on YouTube. There will be plenty more Weekly Extractions in the weeks to come.